Media headlines about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.2417530574128 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several analysts have commented on the stock. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research cut shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Cowen and Company set a $3.00 price objective on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, ValuEngine upgraded shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Alimera Sciences presently has an average rating of “Hold” and a consensus price target of $3.38.
Alimera Sciences (ALIM) traded down $0.01 during trading on Wednesday, hitting $1.20. 147,700 shares of the stock were exchanged, compared to its average volume of 387,864. Alimera Sciences has a one year low of $1.04 and a one year high of $1.72. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Week Herald and is owned by of Week Herald. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://weekherald.com/2017/11/16/alimera-sciences-alim-given-media-impact-score-of-0-17.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.